Company news
Palvella Therapeutics, Inc. news in 2023
Palvella Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.
Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
August 16, 2023
Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring
July 17, 2023
Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study
June 20, 2023
Pieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International Conference
May 21, 2023
Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference
May 20, 2023
Pieris Pharmaceuticals to Host First Quarter 2023 Investor Call and Provide Corporate Update on May 10, 2023
May 1, 2023
Pieris Pharmaceuticals Reports Full-Year 2022 Financial Results and Business Updates
March 28, 2023
Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of CD228 x 4-1BB Bispecific Molecule (Mabcalin SGN-BB228 (PRS-346)
January 9, 2023